Head-to-head evidence
Bevacizumab vs PF-06439535
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
Bevacizumab
Marketed by Roche
NCT00806923 · Phase 3 · completed
This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06447662 (registry estimate)
PF-06439535
Marketed by Pfizer
NCT02364999 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bevacizumab's landscape · PF-06439535's landscape